= Emerging. More than 5 years before clinical availability. (26.55%)
= Expected to be clinically available in 1 to 4 years. (39.66%)
= Clinically available now. (33.79%)
MSACL 2020 US : Thompson

MSACL 2020 US Abstract

Topic: Practical Training

Podium Presentation in Room 6 on Thursday at 9:00 (Chair: Will Thompson / Judy Stone)

System Suitability and Real-time Quality Control Using Skyline and Panorama

J. Will Thompson, Chris Shuford, Mike MacCoss

Presenter Bio(s): Michael MacCoss is Professor of Genome Sciences at the University of Washington. Chris Shuford is Associate Vice President of Research and Development, Laboratory Corporation of America. J. Will Thompson is Assistant Director of the Proteomics and Metabolomics Shared Resource, Research Assistant Professor in the Department of Pharmacology and Cancer Biology at Duke University.

Authors: J. Will Thompson (1), Chris Shuford (2), Michael J. MacCoss (3)
(1) Duke University, Durham NC (2) Laboratory Corporation of America, Burlington, NC (3) University of Washington, Seattle WA

Abstract

Session Description

Although most clinical laboratories perform system suitability testing (SST) prior to

performing analyses, most often the evaluation of these SST data is not quantitative,

and may not be tracked longitudinally. Quality Control (QC) metrics of a sample

batch, additionally, is typically only performed after completion of the study batch.

The combination of Skyline and Panorama workflows allow real time, quantitative

evaluation of SST and QC data to quickly identify system problems or batches that

fail; utilizing this resource routinely should lead to improved system and laboratory uptime.

Take home "Pearls" *

1. Setup of Skyline for any small molecule or peptide targets of interest;

2. How to utilize Skyline for quantitative evaluation of retention time, peak

area, and peak shape;

3. How to enable AutoQC and Panorama along with control charts to perform

SST evaluation and real-time QC.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no